Edwards Lifesciences (NYSE:EW) Issues Q1 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its first quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.700-0.760 for the period, compared to the consensus estimate of 0.690. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Edwards Lifesciences Stock Up 0.3%

Edwards Lifesciences stock traded up $0.20 during midday trading on Tuesday, hitting $77.00. 6,543,660 shares of the stock were exchanged, compared to its average volume of 4,197,906. Edwards Lifesciences has a 1 year low of $65.94 and a 1 year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The firm has a market cap of $44.68 billion, a P/E ratio of 33.19, a P/E/G ratio of 3.03 and a beta of 0.94. The company has a 50 day moving average price of $83.98 and a two-hundred day moving average price of $81.16.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.03). Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on EW shares. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research note on Monday, January 12th. The Goldman Sachs Group restated a “buy” rating and issued a $108.00 target price on shares of Edwards Lifesciences in a research note on Friday, January 9th. Jefferies Financial Group set a $98.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a research report on Monday, November 3rd. Finally, Mizuho boosted their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $96.77.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the transaction, the vice president owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. The trade was a 26.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 43,804 shares of company stock valued at $3,699,082. Insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter valued at about $25,000. Rakuten Securities Inc. raised its position in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Kelleher Financial Advisors acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at about $50,000. Chapman Financial Group LLC bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at about $63,000. Finally, Financial Life Planners acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $93,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.